ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has begun enrolling patients in a pivotal phase III safety trial utilizing glycopyrrolate to treat chronic, moderate-to-severe drooling in pediatric patients. This condition often results from cerebral palsy, as well as other neurological disorders. This trial has been designed to evaluate safety parameters for the six-month period during which patients are expected to be on active treatment.
